Search results
Pages
-
- Management of primary metastatic breast cancer in elderly patients-An international comparison of oncogeriatric versus standard care
-
- Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial
-
- Target volume delineation in breast conserving radiotherapy: are co-registered CT and MR images of added value?
-
- Development of a Decision Aid about fertility preservation for women with breast cancer in the Netherlands
-
- Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients
-
- Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy
-
- International variation in physicians' attitudes towards prophylactic mastectomy - Comparison between France, Germany, the Netherlands and the United Kingdom
-
- Breast cancer stories on the internet : improving search facilities to help patients find stories of similar others
-
- Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial
-
- Left-sided breast cancer radiotherapy with and without breath-hold: Does IMRT reduce the cardiac dose even further?
-
- Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
-
- Comparison of the sentinel node procedure between patients with multifocal and unifocal breast cancer in the EORTC 10981-22023 AMAROS Trial: Identification rate and nodal outcome
-
- Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
-
- Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - Recommendations for clinical guidance
-
- The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial